Advertisement

Donor Evaluation for Hematopoietic Stem and Progenitor Cell Collection

  • Laura S. Connelly-SmithEmail author
Chapter
Part of the Advances and Controversies in Hematopoietic Transplantation and Cell Therapy book series (ACHTCT)

Abstract

With the increasing incidence of hematopoietic allogeneic cell transplantation (allo-HCT), the importance of securing a cellular product, safely from a donor, and ensuring that the product is without additional risk to the recipient, continues to be of paramount importance. The evaluation of the donor’s medical eligibility and suitability is designed to identify and limit the risk of transmitting infectious, genetic, or neoplastic diseases to the recipient through the product. It also aims to ensure a maximum level of safety for the donor and informs them of the risks of donation. Several regulatory agencies, national and international registries, and accreditation bodies have facilitated the availability and safe provision of human cells, tissues, and cellular- and tissue-based products not only at local institutions but also through international exchange.

Keywords

Donor Evaluation Eligibility Suitability Donor safety AABB Cell Collection NMDP 

References

  1. AABB (n.d.-a) AABB HPC, Apheresis and HPC, Marrow DHQ Version 1.6, December 2016. http://www.aabb.org/tm/questionnaires/Documents/dhqhpc/v1-6/DHQ-HPC_A-M%20v1.6.pdf. Accessed 1 May 2017
  2. AABB (n.d.-b) AABB HPC, Apheresis and HPC, Marrow DHQ Version 1.6, December 2016. Flow Charts. http://www.aabb.org/tm/questionnaires/Documents/dhqhpc/v1-6/Flowcharts%20A-M%20v1.6.pdf. Accessed 1 May 2017
  3. Al-Ali HK, Bourgeois M, Krahl R et al (2011) The impact of the age of HLA-identical siblings on mobilization and collection of PBSCs for allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 46:1296–1302PubMedCrossRefPubMedCentralGoogle Scholar
  4. Alyea EP, Kim HT, Ho V et al (2005) Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 105(4):1810–1814PubMedCrossRefPubMedCentralGoogle Scholar
  5. Anthias C, van Walraven SM, Sørensen BS (2015) Related hematopoietic cell donor care: is there a role for unrelated donor registries? Bone Marrow Transplant 50(5):637–641PubMedCrossRefPubMedCentralGoogle Scholar
  6. Anthias C, O’Donnell PV, Kiefer DM et al (2016a) European Group for Blood and Marrow Transplantation Centers with FACT-JACIE accreditation have significantly better compliance with related donor care standards. Biol Blood Marrow Transplant 22(3):514–519PubMedCrossRefPubMedCentralGoogle Scholar
  7. Anthias C, Shaw BE, Kiefer DM et al (2016b) Significant improvements in the practice patterns of adult related donor care in US transplantation centers. Biol Blood Marrow Transplant 22(3):520–527CrossRefGoogle Scholar
  8. Bagnara GP, Bonsi L, Strippoli P et al (2000) Hemopoiesis in healthy old people and centenarians: well-maintained responsiveness of CD34+ cells to hemopoietic growth factors and remodeling of cytokine network. J Gerontol A Biol Sci Med Sci 55(2):B61–B70PubMedCrossRefPubMedCentralGoogle Scholar
  9. Bensinger W, Longin K, Appelbaum F et al (1994) Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 87:825–831PubMedCrossRefPubMedCentralGoogle Scholar
  10. Bensinger W, Appelbaum F, Rowley S et al (1995) Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 13:2547–2555PubMedCrossRefPubMedCentralGoogle Scholar
  11. Billen A, Madrigal JA, Shaw BE (2014) A review of the haematopoietic stem cell donation experience: is there room for improvement? Bone Marrow Transplant 49(6):729–736PubMedCrossRefGoogle Scholar
  12. Boo M, van Walraven SM, Chapman J et al (2011) Remuneration of hematopoietic stem cell donors: principles and perspective of the World Marrow Donor Association. Blood 117:21–25PubMedCrossRefGoogle Scholar
  13. Campbell-Fontaine A, Coad JE, Kovach R et al (2005) Adoptive transfer of vitiligo after allogeneic peripheral blood stem cell transplant. Bone Marrow Transplant 36(8):745–746PubMedCrossRefGoogle Scholar
  14. Center for International Blood and Marrow Transplant Research (CIBMTR) (2016) Summary Slides . http://www.cibmtr.org/ReferenceCenter/SlidesReports/SummarySlides/pages/index.asp. Accessed 1 May 2017
  15. Centers for Disease Control and Prevention (n.d.) Areas with risk of Zika Virus. https://www.cdc.gov/zika/geo/index.html. Accessed 15 Aug 2017
  16. Centers for Disease Control and Prevention (2016) National Notifiable Diseases Surveillance System (NNDSS). https://wwwn.cdc.gov/nndss/conditions/zika/. Accessed May 2017
  17. Clare S, Mank A, Stone R et al (2010) Management of related donor care: a European survey. Bone Marrow Transplant 45:97–101PubMedCrossRefGoogle Scholar
  18. Committee on Bioethics (2010) Children as hematopoietic stem cell donors. Pediatrics 125:392–404CrossRefGoogle Scholar
  19. Confer DL, Shaw BE, Pamphilon DH et al (2011) WMDA guidelines for subsequent donations following initial BM or PBSCs. Bone Marrow Transplant 46:1409–1412PubMedCrossRefGoogle Scholar
  20. Ertem M, Kurekci AE, Aysev D et al (2000) Brucellosis transmitted by bone marrow transplantation. Bone Marrow Transplant 26:225–226PubMedCrossRefGoogle Scholar
  21. Food and Drug Administration (2016) Donor Screening Recommendations to Reduce the Risk of Transmission of Zika Virus by Human Cells, Tissues, and Cellular and Tissue-Based Products. Guidance for Industry. . https://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/tissue/ucm488582.pdf. Accessed 1 May 2017
  22. Food and Drug Administration (2017) Zika virus response updates from the FDA. https://www.fda.gov/EmergencyPreparedness/Counterterrorism/MedicalCountermeasures/MCMIssues/ucm485199.htm. Accessed 1 May 2017
  23. Food and Drug Administration, HHS (2005) Human cells, tissues, and cellular and tissue-based products; donor screening and testing, and related labeling. Fed Regist 70(100):29949–29952Google Scholar
  24. Ghada A, Guthrie KA, Sorror ML et al (2006) Apheresis safety and product yield among elderly donors for allogeneic sibling hematopoietic stem cell transplantation (HST). Blood 108:abstract 5223CrossRefGoogle Scholar
  25. Goker H, Etgul S, Buyukasik Y (2015) Optimizing mobilization strategies in difficult-to-mobilize patients: the role of plerixafor. Transfus Apher Sci 53:23–29PubMedCrossRefGoogle Scholar
  26. Goodnough LT, Marques MB (2017) Zika virus and patient blood management. Anesth Analg 124(1):282–289PubMedCrossRefGoogle Scholar
  27. Gratwohl A, Baldomero H, Aljurf M et al (2010) Hematopoietic stem cell transplantation A Global Perspective. JAMA 303(16):1617–1624PubMedPubMedCentralCrossRefGoogle Scholar
  28. Gratwohl A, Baldomero H, Passweg J (2013) Hematopoietic stem cell transplantation activity in Europe. Curr Opin Hematol 20:485–493PubMedCrossRefPubMedCentralGoogle Scholar
  29. Grupp SA, Frangoul H, Wall D et al (2006) Use of G-CSF in matched sibling donor pediatric allogeneic transplantation: a consensus statement from the Children’s Oncology Group (COG) Transplant Discipline Committee and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive Committee. Pediatr Blood Cancer 46:414–421PubMedCrossRefPubMedCentralGoogle Scholar
  30. Halter J, Kodera Y, Ispizua AU et al (2009) Severe events in donors after allogeneic hematopoietic stem cell donation. Haematologica 94:94–101PubMedPubMedCentralCrossRefGoogle Scholar
  31. Halter JP, van Walraven SM, Worel N et al (2013) Allogeneic hematopoietic stem cell donation-standardized assessment of donor outcome data: a consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT). Bone Marrow Transplant 48:220–225PubMedPubMedCentralCrossRefGoogle Scholar
  32. Horowitz MM (2012) Does matched unrelated donor transplantation have the same outcome as matched sibling transplantation in unselected patients? Best Pract Res Clin Haematol 25(4):483–486PubMedPubMedCentralCrossRefGoogle Scholar
  33. Human Tissue Authority Regulations (2007) . https://www.hta.gov.uk/policies/eu-tissue-and-cells-directives. Accessed 1 May 2017
  34. Ings SJ, Balsa C, Leverett D et al (2006) Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used. Br J Haematol 134(5):517–525CrossRefGoogle Scholar
  35. Jantunen E, Kuittinen T, Penttilä K et al (2006) High-dose melphalan (200 mg/m2) supported autologous stem cell transplantation is safe and effective in elderly (>or =65 years) myeloma patients: comparison with younger patients treated on the same protocol. Bone Marrow Transplant 37:917–922PubMedCrossRefPubMedCentralGoogle Scholar
  36. Kikuchi H, Ohtsuka E, Ono K et al (2000) Allogeneic bone marrow transplantation-related transmission of human T lymphotropic virus type I (HTLV-I). Bone Marrow Transplant 26:1235–1237PubMedCrossRefPubMedCentralGoogle Scholar
  37. Kinrade LC (1987) Preparation of sibling donor for bone marrow transplant harvest procedure. Cancer Nurs 10:77–81PubMedCrossRefPubMedCentralGoogle Scholar
  38. Kodera Y, Yamamoto K, Harada M et al (2014) PBSC collection from family donors in Japan: a prospective survey. Bone Marrow Transplant 49:195–200PubMedCrossRefPubMedCentralGoogle Scholar
  39. Kollman C, Howe CW, Anasetti C et al (2001) Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 98(7):2043–2051CrossRefGoogle Scholar
  40. Kollman C, Spellman SR, Zhang MJ et al (2016) The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. Blood 127(2):260–267PubMedPubMedCentralCrossRefGoogle Scholar
  41. Lampeter EF, McCann SR, Kolb H (1998) Transfer of diabetes type 1 by bone-marrow transplantation. Lancet 351(9102):568–569PubMedCrossRefPubMedCentralGoogle Scholar
  42. Lau GK, Lee CK, Liang R (1999) Hepatitis B virus infection and bone marrow transplantation. Crit Rev Oncol Hematol 31:71–76PubMedCrossRefPubMedCentralGoogle Scholar
  43. Ljungman P, Lawler M, Asjo B et al (1994) Infection of donor lymphocytes with human T lymphotrophic virus type 1 (HTLV-I) following allogeneic bone marrow transplantation for HTLV-I positive adult T-cell leukaemia. Br J Haematol 88:403–405PubMedCrossRefPubMedCentralGoogle Scholar
  44. Lown RN, Philippe J, Navarro W et al (2014) Unrelated adult stem cell donor medical suitability: recommendations from the World Marrow Donor Association Clinical Working Group Committee. World Marrow Donor Association Clinical Working Group Committee. Bone Marrow Transplant 49(7):880–886PubMedCrossRefPubMedCentralGoogle Scholar
  45. Lysák D, Kořístek Z, Gašová Z et al (2011) Efficacy and safety of peripheral blood stem cell collection in elderly donors; does age interfere? J Clin Apher 26(1):9–16PubMedCrossRefPubMedCentralGoogle Scholar
  46. MacLeod KD, Whitsett SF, Mash EJ et al (2003) Pediatric sibling donors of successful and unsuccessful hematopoietic stem cell transplants (HCST): a qualitative study of their psychosocial experience. J Pediatr Psychol 28:223–231PubMedCrossRefPubMedCentralGoogle Scholar
  47. Medpage Today. Ruling on Paying Stem Cell Donors Stands 2012. https://www.medpagetoday.com/hematologyoncology/hematology/31908. Accessed 1 May 2017
  48. Mejia R, Booth GS, Fedorko DP et al (2012) Peripheral blood stem cell transplant-related Plasmodium falciparum infection in a patient with sickle cell disease. Transfusion 52:2677–2682PubMedPubMedCentralCrossRefGoogle Scholar
  49. Miano M, Labopin M, Hartmann O et al (2007) Haematopoietic stem cell transplantation trends in children over the last three decades: a survey by the paediatric diseases working party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 39:89–99PubMedCrossRefPubMedCentralGoogle Scholar
  50. Miflin G, Charley C, Stainer C (1996) Stem cell mobilization in normal donors for allogeneic transplantation: analysis of safety and factors affecting efficacy. Br J Haematol 95(2):345–348PubMedPubMedCentralCrossRefGoogle Scholar
  51. Miller RA (1996) The aging immune system: primer and prospectus. Science 273(5271):70–74PubMedCrossRefPubMedCentralGoogle Scholar
  52. Morris CL, Siegel E, Barlogie B et al (2003) Mobilization of CD341 cells in elderly patients (>/5 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol 120:413–423PubMedPubMedCentralCrossRefGoogle Scholar
  53. Naohara T, Suzuki G, Masauzi N et al (1997) Positive seroconversion syphilis in a patient with acute lymphocytic leukemia after allogeneic bone marrow transplantation. Rinsho Ketsueki 38:228–230PubMedPubMedCentralGoogle Scholar
  54. National Marrow Donor Program (2002) National marrow donor program standards, 18th edn. National Marrow Donor Program, MinneapolisGoogle Scholar
  55. National Marrow Donor Program (NMDP) (2016). Assessment Tool At Recruitment. https://network.bethematchclinical.org/workarea/downloadasset.aspx?id=5090. Accessed 1 May 2017
  56. National Marrow Donor Program (NMDP) (n.d.-a) Be the Match. Donor Assessment. https://network.bethematchclinical.org/apheresis-and-collection-centers/donor-assessment/. Accessed 1 May 2017
  57. National Marrow Donor Program (NMDP) (n.d.-b) Assessing Non-Medical Factors Affecting Donor Suitability. https://network.bethematchclinical.org/workarea/downloadasset.aspx?id=5082. Accessed 1 May 2017
  58. Niederwieser D, Baldomero H, Szer J et al (2016) Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transplant 51(6):778–785PubMedPubMedCentralCrossRefGoogle Scholar
  59. O’Donnell PV, Pedersen TK, Confer DL et al (2010) Practice patterns for evaluation, consent, and care of related donors and recipients at hematopoietic cell transplantation centers in the United States. Blood 115:5097–5101PubMedPubMedCentralCrossRefGoogle Scholar
  60. Olivares JL, Ramos FJ, Olivé T et al (2002) Autoimmune thyroiditis after bone marrow transplantation in a boy with Wiskott-Aldrich syndrome. J Pediatr Hematol Oncol 24(9):772–776PubMedCrossRefGoogle Scholar
  61. Packman W, Crittenden MR, Schaeffer E et al (1997) Psychosocial consequences of bone marrow transplantation in donor and nondonor siblings. J Dev Behav Pediatr 18:244–253PubMedCrossRefGoogle Scholar
  62. Packman W, Crittenden MR, Rieger Fischer JB et al (2008) Sibling perceptions of the bone marrow transplantation process. J Psychosoc Oncol 4615:81–105Google Scholar
  63. Pingali SR, Champlin RE (2015) Pushing the envelope—nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplant 50(9):1157–1167PubMedPubMedCentralCrossRefGoogle Scholar
  64. Pulsipher MA, Levine JE, Hayashi RJ et al (2005) Safety and efficacy of allogeneic PBSC collection in normal pediatric donors: the pediatric blood and marrow transplant consortium experience (PBMTC) 1996–2003. Bone Marrow Transplant 35:361–367PubMedCrossRefGoogle Scholar
  65. Pulsipher MA, Nagler A, Iannone R et al (2006) Weighing the risks of G-CSF administration, leukopheresis, and standard marrow harvest: ethical and safety considerations for normal pediatric hematopoietic cell donors. Pediatr Blood Cancer 46:422–433PubMedCrossRefGoogle Scholar
  66. Pulsipher MA, Chitphakdithai P, Logan BR et al (2013) Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. Blood 121:197–206PubMedPubMedCentralCrossRefGoogle Scholar
  67. Richa E, Papari M, Allen J et al (2009) Older age but not donor health impairs allogeneic granulocyte colony-stimulating factor (G-CSF) peripheral blood stem cell mobilization. Biol Blood Marrow Transplant 15:1394–1399PubMedCrossRefGoogle Scholar
  68. Rinaldi C, Savignano C, Pasca S et al (2012) Efficacy and safety of peripheral blood stem cell mobilization and collection: a single-center experience in 190 allogeneic donors. Transfusion 52(11):2387–2394PubMedPubMedCentralCrossRefGoogle Scholar
  69. Sacchi N, Costeas P, Hartwell L (2008) Haematopoietic stem cell donor registries: World Marrow Donor Association recommendations for evaluation of donor health. Bone Marrow Transplant 42(1):9–14PubMedCrossRefPubMedCentralGoogle Scholar
  70. Schmidt AH, Mengling T, Hernández-Frederick CJ et al (2017) Retrospective analysis of 37,287 observation years after peripheral blood stem cell donation. Biol Blood Marrow Transplant 17:30302–30306Google Scholar
  71. Shah NN, Wayne AS, Grady C et al (2015) Children as hematopoietic cell donors in research: when is it approvable? Bone Marrow Transplant 50(1):15–19PubMedCrossRefPubMedCentralGoogle Scholar
  72. Shuhart MC, Myerson D, Childs BH et al (1994) Marrow transplantation from hepatitis C virus seropositive donors: transmission rate and clinical course. Blood 84:3229–3235PubMedCrossRefPubMedCentralGoogle Scholar
  73. Snowden JA, Heaton DC (1997) Development of psoriasis after syngeneic bone marrow transplant from psoriatic donor: further evidence for adoptive autoimmunity. Br J Dermatol 137(1):130–132PubMedCrossRefPubMedCentralGoogle Scholar
  74. Strasser SI, McDonald GB (1999) Hepatitis viruses and hematopoietic cell transplantation: a guide to patient and donor management. Blood 93:1127–1136PubMedCrossRefPubMedCentralGoogle Scholar
  75. Styczynski J, Balduzzi A, Gil L et al (2012) Risk of complications during hematopoietic stem cell collection in pediatric sibling donors: a prospective European Group for Blood and Marrow Transplantation Pediatric Diseases Working Party study. Blood 119:2935–2942PubMedCrossRefPubMedCentralGoogle Scholar
  76. Suzuya H, Watanabe T, Nakagawa R et al (2005) Factors associated with granulocyte colony-stimulating factor-induced peripheral blood stem cell yield in healthy donors. Vox Sang 89:229–235PubMedCrossRefPubMedCentralGoogle Scholar
  77. Switzer GE, Bruce J, Kiefer DM et al (2017) Health-related quality of life among older related hematopoietic stem cell donors (>60 Years) is equivalent to that of younger related donors (18 to 60 years): a related donor safety study. Biol Blood Marrow Transplant 23(1):165–171PubMedCrossRefPubMedCentralGoogle Scholar
  78. The Foundation for the Accreditation of Cellular Therapy (FACT) (n.d.). International standards for cellular therapy product collection, processing and adminstration. 5th edition. http://www.factwebsite.org. Accessed 1 May 2017
  79. Thomson JA, Wilson RM, Franklin IM (1995) Transmission of thyrotoxicosis of autoimmune type by sibling allogeneic bone marrow transplant. Eur J Endocrinol 133(5):564–566PubMedCrossRefGoogle Scholar
  80. Villalba R, Fornes G, Alvarez MA et al (1992) Acute Chagas’ disease in a recipient of a bone marrow transplant in Spain: case report. Clin Infect Dis 14:594–595PubMedCrossRefGoogle Scholar
  81. Wendler D, Shah NN, Pulsipher MA et al (2016) Research involving pediatric stem cell donors: a way forward. Clin Trials 13(3):304–310PubMedPubMedCentralCrossRefGoogle Scholar
  82. WHO statement on the first meeting of the International Health Regulations (2005) (IHR 2005) Emergency Committee on Zika virus and observed increase in neurological disorders and neonatal malformations 2016. http://www.who.int/mediacentre/news/statements/2016/1st-emergency-committee-zika/en/. Accessed 1 May 2017
  83. Wiener LS, Steffen-Smith E, Fry T et al (2007) Hematopoietic stem cell donation in children: a review of the sibling donor experience. J Psychosoc Oncol 25:45–66PubMedPubMedCentralCrossRefGoogle Scholar
  84. Worel N, Buser A, Greinix HT et al (2015) Suitability criteria for adult related donors: a consensus statement from the worldwide network for blood and marrow transplantation standing committee on donor issues. Biol Blood Marrow Transplant 21(12):2052–2060PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Apheresis and Cellular Therapy, SCCASeattleUSA
  2. 2.Division of HematologyUW Medical CenterSeattleUSA
  3. 3.Fred HutchSeattleUSA

Personalised recommendations